The BioE3 Policy 2024 envisions a bio-manufacturing-led economy. Discuss its pillars, the Genome India Project’s role in precision medicine, and the regulatory architecture for gene editing.

Introduction:

The BioE3 Policy 2024 (Biotechnology for Economy, Environment and Employment), approved by the Cabinet in August 2024 under the Department of Biotechnology, targets the bio-economy at $300 bn by 2030 and $1.1 trillion by 2047, up from $151 bn in 2023 (India BioEconomy Report 2024).

Pillars: BioE3 builds six thematic verticals — high-value bio-based chemicals, smart proteins, precision biotherapeutics, climate-resilient agriculture, carbon-capture, and marine and space bio-manufacturing. It establishes Bio-AI Hubs, Biofoundries and Biomanufacturing Hubs co-funded with the Anusandhan National Research Foundation Act 2023 (₹50,000 crore over 2023-28).

Genome India Project: The DBT-funded Genome India Project completed whole-genome sequencing of 10,000 individuals across 99 ethnic groups by January 2025 (DBT release). It anchors precision medicine for monogenic disorders such as sickle-cell anaemia — under the National Sickle Cell Anaemia Elimination Mission 2047 (₹1,500 crore, 17 states), 3.6 crore people have been screened. The Indian Biological Data Centre at RCB stores 8 petabytes of sequence data.

Regulatory architecture: GMO clearance under EPA 1986 Rules 1989 by GEAC remains contested — the Bt-brinjal moratorium (2010) and DMH-11 mustard Supreme Court split verdict (July 2024) reflect public-trust gaps. The DNA Technology Bill 2019 lapsed; the BSL-4 lab at NIV Pune handles only ten select agents.

Way forward:

DBT should table the Biosafety and Genetic Engineering Authority Bill by FY27, operationalise BioRRAP and ANRF Biofoundries in 5 cities, and tier Genome India Phase-2 to 1 lakh genomes for SCD, thalassemia and rare-disease precision care.